Similarly, in prostate cancer, the inhibition of the AR pathway activates changes in the FOXA2-dependent transcriptional pattern, driving the adeno-to-neuroendocrine transition, thereby causing castration resistance [271]. The gene discussed is AR; the disease is Familial prostate cancer.